期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
The Effect of Case Management for Schizophrenia Clients in China
1
作者 Jia cheng Huaicun Liu +6 位作者 Tong Geng Yong Wang Ling Yu Jingjing Li Wenxiu Li caili chen Guizhong Yao 《Journal of Behavioral and Brain Science》 2020年第8期297-310,共14页
<strong>Background</strong>: The aim at this study is to establish the effectiveness of case management (CM) compared to care as usual (CAU) in patients with schizophrenia. <strong>Methods</strong... <strong>Background</strong>: The aim at this study is to establish the effectiveness of case management (CM) compared to care as usual (CAU) in patients with schizophrenia. <strong>Methods</strong>: 128 patients with schizophrenia were recruited from the community of Haidian District (Beijing, China), 68 patients in the CM group and 60 patients in the CAU group. Efficacy and safety information were assessed at one year follow-up. The relapse rate was similar in both groups after 12 months followed up (7% and 5%). The withdraw rate was significant lower in CM group compared with CAU group (10% and 36%). <strong>Results</strong>: There is no significant difference in PANSS, PSP and SSMI score between 2 groups at each visit. Between endpoint and baseline, there is a significant improvement on PANSS negative score and PSP in patients treated with CM, while CAU group was not significantly changed. <strong>Conclusions</strong>: There is a possible effectiveness of CM group of improving negative symptoms and social function in schizophrenia clients. 展开更多
关键词 Case Management Care as Usual Schizophrenia Clients PANSS Score
下载PDF
恩替卡韦治疗不同乙型肝炎病毒基因型慢性乙型肝炎疗效分析 被引量:2
2
作者 范倩燕 鲍彩丽 +3 位作者 俞莹 陈颖 夏明镜 殷建华 《中国药业》 CAS 2017年第17期43-45,共3页
目的探讨恩替卡韦治疗不同乙型肝炎病毒(HBV)基因型慢性乙型肝炎疗效。方法选择上海市杨浦区中心医院安图分部2012年1月至2014年12月收治的HBV患者200例,在基因分型后,对其进行恩替卡韦治疗,观察不同基因型患者的疗效。结果第24周,B基... 目的探讨恩替卡韦治疗不同乙型肝炎病毒(HBV)基因型慢性乙型肝炎疗效。方法选择上海市杨浦区中心医院安图分部2012年1月至2014年12月收治的HBV患者200例,在基因分型后,对其进行恩替卡韦治疗,观察不同基因型患者的疗效。结果第24周,B基因型患者HBV DNA阴性转变率为82.35%,C基因型患者则为73.47%;B基因型患者ALT复常率为78.43%,C基因型患者为70.41%。第96周,B,C基因型患者ALT复常率为81.37和71.43%;HBV DNA阴性转变率分别为89.22%和83.67%,HBe Ag阴性转变率分别为13.73%和10.20%;HBe Ag发生血清学转换率分别为10.78%和7.14%。第24,96周临床疗效比较均无显著差异(P>0.05)。结论关于HBV基因型差异对恩替卡韦的抗病毒效果是否有影响尚需进一步探讨,以便更好地指导HBV抗病毒药物治疗与临床疗效的判断。 展开更多
关键词 恩替卡韦 乙型肝炎病毒基因 慢性乙型肝炎
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部